Publications by authors named "Mark A Ator"

Claim this Profile
N
Novel Macrocyclic Antagonists of the Calcitonin Gene-Related Peptide Receptor: Design, Realization, and Structural Characterization of Protein-Ligand Complexes.
Andrew D Cansfield, Mark A Ator, Joydeep Banerjee, Michael Bestwick, Andrea Bortolato

ACS Chem Neurosci· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Drug Discovery of -(()-3-(7-Methyl-1-indazol-5-yl)-1-oxo-1-((()-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of Migraine.
Sarah J Bucknell, Mark A Ator, Alastair J H Brown, Jason Brown, Andrew D Cansfield

J Med Chem· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.
Amar N Mirza, Micah A Fry, Nicole M Urman, Scott X Atwood, Jon Roffey, Mark A Ator

JCI Insight· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor.
Joel Kaye, Victor Piryatinsky, Tal Birnberg, Tal Hingaly, Emanuel Raymond, Mark A Ator

Proc Natl Acad Sci U S A· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).
Gregory R Ott, Mangeng Cheng, Keith S Learn, Jason Wagner, Diane E Gingrich, Mark A Ator

J Med Chem· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-(1'-Cyclobutylspiro[4H-1,3-benzodioxine-2,4'-piperidine]-6-yl)-5,5-dimethyl-1,4-dihydropyridazin-6-one (CEP-32215), a new wake-promoting histamine H3 antagonist/inverse agonist.
Robert L Hudkins, John A Gruner, Rita Raddatz, Joanne R Mathiasen, Lisa D Aimone, Mark A Ator

Neuropharmacology· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cellular Assay for Inhibitors of the Fatty Acid Biosynthetic Pathway Using Scintillating Microplates.
Thao Ung, Jennifer L Mason, Ron G Robinson, Chrysanthe M Spais, Mark A Ator

Assay Drug Dev Technol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase.
Eugen F Mesaros, Thelma S Angeles, Mark S Albom, Jason C Wagner, Lisa D Aimone, Mark A Ator

Bioorg Med Chem Lett· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological evaluation of sulfonyl acrylonitriles as novel inhibitors of cancer metastasis and spread.
Yi Shen, Craig A Zificsak, Jill E Shea, Xuegang Lao, Oana Bollt, Mark A Ator

J Med Chem· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serendipitous discovery of a prodrug of a PARP-1 inhibitor.
Derek Dunn, Jean Husten, Lisa D Aimone, Mark A Ator, Sankar Chatterjee

Chem Biol Drug Des· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From an atypical wake-promoting agent to potent histamine-3 receptor inverse agonists.
Derek Dunn, Rita Raddatz, Mark A Ator, Edward R Bacon, Sankar Chatterjee

Chem Biol Drug Des· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-resolved fluorescence resonance energy transfer as a versatile tool in the development of homogeneous cellular kinase assays.
Lisa Saville, Chrysanthe Spais, Jennifer L Mason, Mark S Albom, Seetha Murthy, Mark A Ator

Assay Drug Dev Technol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of LanthaScreen Eu kinase binding assay and surface plasmon resonance method in elucidating the binding kinetics of focal adhesion kinase inhibitors.
Jennifer L Mason, Chrysanthe Spais, Jean Husten, Eric Prouty, Mark S Albom, Mark A Ator

Assay Drug Dev Technol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wake promoting agents: search for next generation modafinil, lessons learned: part III.
Derek Dunn, Greg Hostetler, Mohamed Iqbal, Val R Marcy, Yin Guo Lin, Mark A Ator

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.
Benjamin J Dugan, Diane E Gingrich, Eugen F Mesaros, Karen L Milkiewicz, Matthew A Curry, Mark A Ator

J Med Chem· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serendipity in discovery of proteasome inhibitors.
Derek Dunn, Mohamed Iqbal, Jean Husten, Mark A Ator, Sankar Chatterjee

Bioorg Med Chem Lett· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.
Diane E Gingrich, Joseph G Lisko, Matthew A Curry, Mangeng Cheng, Matthew Quail, Mark A Ator

J Med Chem· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.
Joyce James, Bruce Ruggeri, Robert C Armstrong, Martin W Rowbottom, Susan Jones-Bolin, Mark A Ator

Mol Cancer Ther· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteasome inhibitors for cancer therapy.
Mohamed Iqbal, Patricia A Messina McLaughlin, Derek Dunn, Satish Mallya, Jean Husten, Mark A Ator

Bioorg Med Chem· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
Mangeng Cheng, Matthew R Quail, Diane E Gingrich, Gregory R Ott, Lihui Lu, Mark A Ator

Mol Cancer Ther· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wake-promoting agents: search for next generation modafinil: part I.
Derek Dunn, Greg Hostetler, Mohamed Iqbal, Patricia Messina-McLaughlin, Alyssa Reiboldt, Mark A Ator

Bioorg Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wake-promoting agents: search for next generation modafinil: part II.
Derek Dunn, Greg Hostetler, Mohamed Iqbal, Patricia Messina-McLaughlin, Alyssa Reiboldt, Mark A Ator

Bioorg Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.
Martin W Rowbottom, Raffaella Faraoni, Qi Chao, Brian T Campbell, Andiliy G Lai, Mark A Ator

J Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.
Robert L Hudkins, Nadine C Becknell, Allison L Zulli, Ted L Underiner, Thelma S Angeles, Mark A Ator

J Med Chem· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel poly(ADP-ribose) polymerase-1 inhibitors.
Derek Dunn, Jean Husten, Mark A Ator, Sankar Chatterjee

Bioorg Med Chem Lett· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis